Imunon Inc (IMNN) Stock Price, Quote & News

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 896 9100

Website: imunon.com

Address:

997 Lenox Drive, Suite 100, Lawrenceville, United States

jjegglie Mar. 20 at 10:22 PM

$IMNN Look out below.

0 · Reply

jjegglie Mar. 19 at 5:54 PM

$IMNN The freefall should accelerate now that its below 3. Was levitating on air. Remember this is a stock promotion scam corporation

0 · Reply

LKDOG Mar. 18 at 5:17 PM

$IMNN Zero Negative information & this os under $3 Ridiculous

1 · Reply

I_AM_GROOT Mar. 18 at 1:40 AM

$IMNN getting closer to 2 then lower 1's where volume increases and day trades become easier. More volatilility at which bigger swings to make back losses from last yr. Rinse / Repeat this is a money making beast if traded correctly.

0 · Reply

Shrekislove69 Mar. 17 at 12:57 PM

$IMNN I wonder if I’ll ever make money on this 😭😂

1 · Reply

jjegglie Mar. 14 at 10:00 PM

$IMNN Been a while since the last major dilution. $5 million cash on hand at the end of Q3 plus $7 million from the end of December dilution event, minus nearly 2 full quarters of cash burn at 4-5 million per quarter, leaves celsion with no more than $4 million on the books. Less than a single quarter. Dilution inbound. Any day now.

0 · Reply

LongBallBarn Mar. 13 at 9:15 PM

$IMNN huh

1 · Reply

mazzzzzzz Mar. 13 at 4:51 PM

$IMNN ?????

1 · Reply

Bio_Be_Dirty Mar. 11 at 7:04 PM

$IMNN eventually

1 · Reply

RaKa82 Mar. 10 at 8:03 PM

$IMNN https://www.linkedin.com/posts/ovariancancer-immunotherapy-gynecologiconcology-share-7437163390449631232-if2h?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAAM2iqoBmhYzUb3nBviL14tvp7OhH4yaRpI&utm_campaign=copy_link

0 · Reply

IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY

Dec 30, 2025, 8:30 AM EST - 2 months ago

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

Dec 29, 2025, 11:10 AM EST - 2 months ago

IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026

Nov 13, 2025, 7:45 AM EST - 4 months ago

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 1:30 PM EST - 4 months ago

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

Nov 10, 2025, 7:30 AM EST - 4 months ago

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

Nov 7, 2025, 8:05 AM EST - 4 months ago

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

Nov 6, 2025, 8:05 AM EST - 4 months ago

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

Nov 4, 2025, 8:05 AM EST - 4 months ago

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 30, 2025, 8:00 AM EDT - 5 months ago

IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting

Oct 23, 2025, 10:01 AM EDT - 5 months ago

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

Oct 20, 2025, 8:05 AM EDT - 5 months ago

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 17, 2025, 8:10 AM EDT - 5 months ago

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

Oct 14, 2025, 8:20 AM EDT - 5 months ago

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

Sep 22, 2025, 8:05 AM EDT - 6 months ago

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

Sep 19, 2025, 8:05 AM EDT - 6 months ago

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

Aug 28, 2025, 8:05 AM EDT - 7 months ago

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Aug 5, 2025, 4:00 PM EDT - 8 months ago

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Aug 5, 2025, 8:00 AM EDT - 8 months ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Jul 29, 2025, 8:30 AM EDT - 8 months ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

Jul 28, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 23, 2025, 8:00 AM EDT - 8 months ago

IMUNON Announces Reverse Stock Split

Jul 15, 2025, 8:05 AM EDT - 8 months ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jun 18, 2025, 8:05 AM EDT - 9 months ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 17, 2025, 8:05 AM EDT - 9 months ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 3, 2025, 8:05 AM EDT - 10 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 2, 2025, 8:05 AM EDT - 10 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

May 27, 2025, 8:05 AM EDT - 10 months ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 23, 2025, 6:59 PM EDT - 10 months ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 8:05 AM EDT - 10 months ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 22, 2025, 5:20 PM EDT - 10 months ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 15, 2025, 8:05 AM EDT - 11 months ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 12, 2025, 8:00 AM EDT - 11 months ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 11 months ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025, 8:05 AM EDT - 11 months ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 5, 2025, 8:00 AM EDT - 11 months ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

Apr 21, 2025, 8:05 AM EDT - 11 months ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 1 year ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Feb 27, 2025, 8:05 AM EST - 1 year ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 26, 2025, 8:05 AM EST - 1 year ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 20, 2025, 8:30 AM EST - 1 year ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 19, 2025, 8:05 AM EST - 1 year ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 10, 2025, 8:05 AM EST - 1 year ago

IMUNON Appoints Douglas V. Faller, M.D.

Dec 19, 2024, 8:05 AM EST - 1 year ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Dec 10, 2024, 8:05 AM EST - 1 year ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Nov 25, 2024, 8:05 AM EST - 1 year ago

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

Nov 7, 2024, 10:00 AM EST - 1 year ago

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

Nov 7, 2024, 8:05 AM EST - 1 year ago

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 31, 2024, 8:30 AM EDT - 1 year ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

jjegglie Mar. 20 at 10:22 PM

$IMNN Look out below.

0 · Reply

jjegglie Mar. 19 at 5:54 PM

$IMNN The freefall should accelerate now that its below 3. Was levitating on air. Remember this is a stock promotion scam corporation

0 · Reply

LKDOG Mar. 18 at 5:17 PM

$IMNN Zero Negative information & this os under $3 Ridiculous

1 · Reply

I_AM_GROOT Mar. 18 at 1:40 AM

0 · Reply

Shrekislove69 Mar. 17 at 12:57 PM

$IMNN I wonder if I’ll ever make money on this 😭😂

1 · Reply

jjegglie Mar. 14 at 10:00 PM

0 · Reply

LongBallBarn Mar. 13 at 9:15 PM

$IMNN huh

1 · Reply

mazzzzzzz Mar. 13 at 4:51 PM

$IMNN ?????

1 · Reply

Bio_Be_Dirty Mar. 11 at 7:04 PM

$IMNN eventually

1 · Reply

RaKa82 Mar. 10 at 8:03 PM

0 · Reply

RaKa82 Mar. 10 at 8:02 PM

$IMNN they continue to remain visible

0 · Reply

SwingPlayers Mar. 10 at 7:33 PM

$TAN $CLN $KBW

0 · Reply

ConcernedCitizen23 Mar. 10 at 6:58 PM

$IMNN seems like the “earnings” will just be a restatement of their clinical trial progress. They have some money in the bank to get through the spring maybe summer. Just waiting for someone to buy them. I bet they have 50+ pts already with 7 active sites for phase 3. They fumbled their chance to be taken over in 2024 so now we wait for round 2. I think it’s worth at least $250 million if not $500 mill as is but they need to hustle to get bids

3 · Reply

RaKa82 Mar. 9 at 3:26 PM

$IMNN nibbled a bit today. Continued silence on earnings 🤔

1 · Reply

Cabone512 Mar. 8 at 4:10 PM

$IMNN got no choice but to go up from here waiting on good news

0 · Reply

Jacks10 Mar. 6 at 9:27 PM

$IMNN wth! With after hours!

2 · Reply

jjegglie Mar. 6 at 7:20 PM

$IMNN @ananashraf you're embarrassing yourself by hanging an article that cites serial lying carnival barker @ConcernedCitizen23 in any way except as a joke and cautionary tale.

0 · Reply

LongBallBarn Mar. 6 at 1:25 PM

$PRSO $AIFF $BNAI $IMNN New beach house day lol

0 · Reply

RaKa82 Mar. 5 at 4:11 PM

$IMNN

0 · Reply

RaKa82 Mar. 3 at 4:15 PM

$IMNN trading volume has really dried up here lately. Wonder why

0 · Reply

RaKa82 Mar. 2 at 9:07 PM

$IMNN closed green in a sea of red. She has a mind of her own. Not bad.

0 · Reply

RaKa82 Mar. 2 at 3:00 PM

$IMNN Just a reminder of what we could have here

0 · Reply

Market Cap	9.12M
Revenue (ttm)	0.00
Net Income (ttm)	-18.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	50,600
Avg Vol	32,498
Day's Range	N/A - N/A
Shares Out	3.07M
Stochastic %K	2%
Beta	2.06
Analysts	Strong Sell
Price Target	$21.50